Amporin Pharmaceuticals AG

Amporin Pharmaceuticals AG is developing a breakthrough new class of small molecule amyloid pore inhibitors that can uniquely protect and repair cell and mitochondrial membranes from the damage caused by toxic soluble misfolded protein oligomers, allowing diseased cells to fully recover and restore homeostasis. Our first-in-class oral drug molecules could stop and potentially even reverse the progression of over 50 deadly degenerative diseases, including Alzheimer's and Parkinson's disease, type II diabetes, and many rare diseases. Together, these diseases affect over half a billion people and kill 3.6 million people each year at a total cost of USD 3 trillion per year. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson's disease.